PROJECT TITLE: Multifunctional Nanoassemblies for Ligand-Directed Imaging and Therapy of Endocrine Pancreatic Tumors PROJECT SUMMARY: The development of tools for the targeted delivery of Imaging-probes and therapeufic agents has become the focus of intense efforts in the context of many human diseases. The in vivo screening method in which phage can be selected from engineered combinatorial peptide libraries for their ability to target specific vascular beds has uncovered a vascular address system that allows specific angiogenesis-related targeting to blood vessels in cancer. This phage display-based targeting Is expanded by the direct-assembly of gold and nanoporous silicon nanoparticles onto phage for nanomedical applications. Through exploiting the nanodimensions of the phage particle as a molecular network we generated biologically active nanoassemblies (NAs) with concomitant unique and tunable chemical and physical properties. These properties include near-infrared (NIR) radiation conversion to heat, enhancement of fluorescent signals, NIR surface enhanced Raman scattering (SERS) and the ability to conjugate and incorporate therapies or imaging-tracers. This tuning capability combined with the programmable tissue targefing affords the Integrafion of multiple funcfionalities into a single NA and serves as a complementary and non-mutually exclusive tool among different applicafions, including chemotherapy targeting and molecular imaging. Project 4 aims to develop the ligand-directed Si particles- phage- Au particles NAs as novel systems for targeted imaging and therapy in endocrine pancreatic tumors. These efforts will be translated into wide-ranging clinical applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151668-05
Application #
8735865
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
2014-08-01
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$330,151
Indirect Cost
$36,085
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Ornelas, Argentina; McCullough, Christopher R; Lu, Zhen et al. (2016) Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16:824
Zacharias, Niki M; McCullough, Christopher R; Wagner, Shawn et al. (2016) Towards Real-time Metabolic Profiling of Cancer with Hyperpolarized Succinate. J Mol Imaging Dyn 6:
Hatakeyama, Hiroto; Wu, Sherry Y; Mangala, Lingegowda S et al. (2016) Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 1402:189-97
Hosoya, Hitomi; Dobroff, Andrey S; Driessen, Wouter H P et al. (2016) Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release. Proc Natl Acad Sci U S A 113:1877-82
Tasciotti, Ennio; Cabrera, Fernando J; Evangelopoulos, Michael et al. (2016) The Emerging Role of Nanotechnology in Cell and Organ Transplantation. Transplantation 100:1629-38
Au Yeung, Chi Lam; Co, Ngai-Na; Tsuruga, Tetsushi et al. (2016) Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7:11150
Zhou, Min; Melancon, Marites; Stafford, R Jason et al. (2016) Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy. J Nucl Med 57:1778-1783
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :
Mi, Yu; Wolfram, Joy; Mu, Chaofeng et al. (2016) Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacol Res 113:92-99
Rupaimoole, R; Ivan, C; Yang, D et al. (2016) Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35:4312-20

Showing the most recent 10 out of 308 publications